Novoprotein(SH:688137) Zheng Quan Zhi Xing·2025-08-27 11:24Core Viewpoint - The company is committed to enhancing operational quality and investor returns through its "Quality Improvement and Efficiency Enhancement Action Plan" for 2025, focusing on core competencies in recombinant protein technology and applications [1][2]. Group 1: Business Performance - The company achieved a revenue of 72.09 million yuan in the first half of 2025, representing a year-on-year increase of 20.85%, driven by improved management, product quality, and expansion into overseas markets [2]. - The recombinant protein business saw a significant growth of 43.66% year-on-year, while the overall customer base increased by 4.2% [2][6]. - The net profit attributable to shareholders was -24.22 million yuan, primarily due to high R&D and marketing investments aimed at high-quality development and reduced government subsidies [2][6]. Group 2: R&D and Innovation - The company emphasizes self-innovation, with 23 core technologies forming 7 comprehensive technology platforms, enhancing its capabilities in product development, production, and quality control [6][7]. - The company is actively developing solutions for various drug types, including RNA vaccines and antibody drugs, and is focusing on areas like organoids and three-dimensional genomics in life sciences [7][8]. Group 3: Investor Relations and Governance - The company has repurchased 404,337 shares for a total of approximately 11.96 million yuan to enhance investor confidence and maintain long-term investment value [8][9]. - The company adheres to strict information disclosure practices, ensuring transparency and communication with investors through multiple channels [9][10]. - The governance structure is continuously optimized to ensure compliance with legal regulations and to protect shareholder rights [10][11]. Group 4: Market Expansion - The company is expanding its overseas market presence by building localized teams and participating in international exhibitions related to antibody drugs and gene therapies [4][5]. - The number of overseas customers increased significantly, reflecting the company's successful market penetration strategies [5]. Group 5: Operational Efficiency - The company is implementing cost-reduction measures and enhancing production efficiency through supply chain integration and local sourcing of raw materials [3][6]. - Quality management systems such as GMP and ISO standards are strictly followed to ensure product safety and effectiveness [3][6]. Group 6: Future Outlook - The company plans to continue evaluating the execution of its action plan while focusing on core business areas and exploring new profit growth points [11]. - The commitment to sustainable long-term returns for investors remains a priority, alongside maintaining operational excellence [11].